Brave Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Brave Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-500	Closed	-$2K	–	366
2016 Q3	$2K	Hold	500	–	–	﹤0.01%	373
2016 Q2	$2K	Hold	500	–	–	﹤0.01%	386
2016 Q1	$2K	Hold	500	–	–	﹤0.01%	411
2015 Q4	$2K	Hold	500	–	–	﹤0.01%	416
2015 Q3	$2K	Hold	500	–	–	﹤0.01%	407
2015 Q2	$3K	Hold	500	–	–	﹤0.01%	414
2015 Q1	$3K	Buy	+500	New	+$2.89K	﹤0.01%	407

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brave Asset Management's ECYT Position: Q4 2016 in Review

Brave Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2016, closing a stake of 500 shares — an estimated $2K sold.

Brave Asset Management first reported a position in ECYT in Q1 2015 and held it in 7 quarters. The position peaked at $3K in Q2 2015. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

Brave Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Brave Asset Management sold 500 Endocyte, Inc. Common Stock shares in Q4 2016, an estimated $2K.
Brave Asset Management first reported a position in Endocyte, Inc. Common Stock in Q1 2015 and held it in 7 quarters.
Brave Asset Management's Endocyte, Inc. Common Stock position peaked at $3K in Q2 2015.
96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on Brave Asset Management's 13F filing for Q4 2016, filed 27 Jan 2017.